Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 20 → 21·03:35, 15 Oct 2024
Difference between revision 20 and revision 21 of Glucose-dependent insulinotropic polypeptide. 1 line changed; the page grew by 233 bytes.
| Revision 20 — 18:28, 5 Oct 2024 ColdChainCleo (talk) add DOI 5,034 bytes ±0 | Revision 21 — 03:35, 15 Oct 2024 CiteBot (talk) bot: update parent category chain 5,267 bytes +233 | ||
|---|---|---|---|
| 11 | | Plasma half-life = 7 minutes | 11 | | Plasma half-life = 7 minutes |
| 12 | }} | 12 | }} |
| + | 13 | {{hatnote|Formerly known as glucose-dependent insulinotropic peptide (GIP). For the GLP-1 arm of the incretin axis, see [[Glucagon-like peptide-1]]. For the receptor it acts on, see [[GLP-1 receptor agonist]] for clinical context.}} | |
| 13 | 14 | ||
| 14 | '''Glucose-dependent insulinotropic polypeptide''' ('''GIP'''), also termed '''glucose-dependent insulinotropic peptide''', is a 42-residue [[peptide]] hormone secreted by enteroendocrine K cells of the duodenum and proximal jejunum in response to the ingestion of glucose, fat and amino acids. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucagon-like peptide-1]] (GLP-1).{{r|nauck2019}} | 15 | '''Glucose-dependent insulinotropic polypeptide''' ('''GIP'''), also termed '''glucose-dependent insulinotropic peptide''', is a 42-residue [[peptide]] hormone secreted by enteroendocrine K cells of the duodenum and proximal jejunum in response to the ingestion of glucose, fat and amino acids. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucagon-like peptide-1]] (GLP-1).{{r|nauck2019}} |